Wolfgang Miesbach: First AAV Gene Therapy Data in Adolescents With Haemophilia B
Wolfgang Miesbach, Head of the Hemostasis and Hemophilia Center at Department of Medicine II, University Hospital Frankfurt, shared a post on LinkedIn about a recent article by Feng Xue at el., published in Nature Medicine, adding:
“A first AAV gene therapy for haemophilia B in adolescents. Xue and colleagues report in Nature Medicine a multicentre phase 1 trial of BBM-H901 (dalnacogene ponparvovec, FIX-Padua, AAV843) in 11 boys aged 12–18 with severe or moderately severe haemophilia B, at 5 × 10¹² vg/kg — the adult dose:
No dose-limiting toxicity. One SAE, unrelated to the vector; transaminitis in one participant, resolved under immunosuppression.
Mean FIX:C at week 52: 41.8 IU/dL (SynthASil) but 26.4 IU/dL (Actin FSL) – a reagent ratio of 1.49, a reminder that the assay shapes the message.
ABR 13.9 to 0.5; 82% bleed-free; no target joints at week 52.
The kinetics are the interesting part. Adolescents peaked higher than adults (106 vs 98 IU/dL) yet fell further by week 52 (42 vs 55 IU/dL). Nearly three-quarters dropped early, at weeks 2–4, and four lost expression durably.
Hepatocyte proliferation in a growing liver, diluting episomal vector, is the obvious explanation – but unproven, and the single-cell data point instead to immune activation on glucocorticoid withdrawal.”
Title: Factor IX Padua AAV gene therapy in adolescents with hemophilia B: a phase 1 trial
Authors: Feng Xue, Ai Zhang, Mankai Ju, Xia Wu, Bingqi Xu, Xiaolei Pei, Yuhua Wang, Wei Liu, Aiguo Liu, Wei Jiang, Xinyue Dai, Yunfei Chen, Xiaofan Liu, Rongfeng Fu, Ting Sun, Wenjing Gu, Jing Zheng, Zengmin Du, Caifeng Yang, Xiao Xiao, Renchi Yang, Qun Hu, Lei Zhang
Other posts featuring Wolfgang Miesbach on Hemostasis Today.
-
Sep 22, 2026, 04:43Michael Cahillane: Highlights From BBTS2026 in Glasgow
-
Sep 22, 2026, 04:03Emmanuel J Favaloro: 100 Years of VWD – A Special Virtual Issue
-
Sep 22, 2026, 03:31Mostafa Elshazly: How Is Humidification Used During Non Invasive Ventilation?
-
Sep 22, 2026, 03:05Sumyea Kabir: Jehovah’s Witnesses Update Their Position on Blood Components
-
Sep 22, 2026, 02:33Gerardo Moscatelli: The Spike Protein Cascade – From Endothelial Binding to Vascular Collapse
-
Sep 21, 2026, 20:56George Touma: ApoB Should Be Central to All Lipid Guidlines
-
Sep 21, 2026, 20:55Christopher Robinson: Obstetric Risks Are Seen at the Extremes of Birthweight
-
Sep 21, 2026, 20:54Emicizumab for Refractory GI Bleeding in Myeloma-Associated Acquired VWD – JTH
-
Sep 21, 2026, 20:52Ross Baker: ASH 2026 Guidelines on Iron Deficiency in HMB and Bleeding Disorders